Search

Your search keyword '"Mairéad G. McNamara"' showing total 248 results

Search Constraints

Start Over You searched for: Author "Mairéad G. McNamara" Remove constraint Author: "Mairéad G. McNamara"
248 results on '"Mairéad G. McNamara"'

Search Results

1. Systemic Therapy for Metastatic Pancreatic Cancer—Current Landscape and Future Directions

2. Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma

3. The Management and Outcomes of Patients with Extra-Pulmonary Neuroendocrine Neoplasms and Brain Metastases

4. NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinomaResearch in context

5. Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: a review

6. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre‐specified subgroup analysis of the randomized CASSINI study

7. Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis

8. Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI Trial

9. Targeting PD-1/PD-L1 in biliary tract cancer: role and available data

12. Use of the Rockwood Clinical Frailty Scale in patients with advanced hepatopancreaticobiliary malignancies

13. Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma

14. Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes

15. Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma

16. Supplementary Methods, Figures 1 - 2 from Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

17. Data from Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

18. High rate of Ki-67 increase in entero-pancreatic NET relapses after surgery with curative intent

19. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

20. Prospective Observational Study of Prevalence, Assessment and Treatment of Pancreatic Exocrine Insufficiency in Patients with Inoperable Pancreatic Malignancy (PANcreatic Cancer Dietary Assessment—PanDA)

21. Outcomes in older patients with biliary tract cancer

23. Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy

24. Targeted Therapies for Perihilar Cholangiocarcinoma

25. Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module)

26. A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)

27. Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer

28. Clinical and Translational Research Challenges in Biliary Tract Cancers

29. Current Translational and Clinical Challenges in Advanced Hepatocellular Carcinoma

30. Molecular targeted therapies: Ready for 'prime time' in biliary tract cancer

31. Extrapulmonary poorly differentiated NECs, including molecular and immune aspects

32. Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives

33. Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI Trial

34. Liver Embolisation for Patients with Neuroendocrine Neoplasms: Systematic Review

35. Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer

39. Relevant Study: Patient and Clinician Perspectives on Clinically-Meaningful Outcomes in Advanced Pancreatic Cancer

40. Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary

41. Pancreatic Enzyme Replacement Therapy for Patients Diagnosed With Pancreaticobiliary Cancer: Validation of an Algorithm for Dose Escalation and Management

42. What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literature

43. Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis

44. Potential utility of liquid biopsies in the management of patients with biliary tract cancers: A review

45. Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis

46. Fluorothymidine Positron Emission Tomography (FLT-PET) Repeatability and Response Evaluation in Advanced Pancreatic Cancer Patients Treated with Gemcitabine-Based Chemotherapy

47. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres

48. Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes

49. Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes

50. 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis

Catalog

Books, media, physical & digital resources